CORRECTION article

Front. Cardiovasc. Med., 16 March 2023

Sec. Cardiovascular Metabolism

Volume 10 - 2023 | https://doi.org/10.3389/fcvm.2023.1172664

Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)

  • 1. Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan

  • 2. Caress Sapporo Hokko Memorial Clinic, Sapporo, Japan

  • 3. Hiramitsu Heart Clinic, Nagoya, Japan

  • 4. Keiyukai Yoshida Hospital, Asahikawa, Japan

  • 5. Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan

  • 6. Department of Social and Environmental Medicine, Kanazawa Medical University, Uchinada, Japan

In the published article, there was an error in Table 6 (Adverse events) as published. The error was found in the percentage of participants with sepsis associated with enteritis in the PEMA group. The corrected table appears below.

Table 6

PEMA (n = 63)OMEGA-3 (n = 63)
AEs9 (14.3)3 (4.8)
Participants who discontinued treatment because of drug-related AE
Nausea1 (1.6)0 (0.0)
Pain in the extremities1 (1.6)0 (0.0)
Erythema on the forearm1 (1.6)0 (0.0)
Itching in the forearm1 (1.6)0 (0.0)
General malaise1 (1.6)0 (0.0)
Anorexia1 (1.6)0 (0.0)
Participants who discontinued treatment because of drug-unrelated AE
Neck stiffness1 (1.6)0 (0.0)
Tooth pain1 (1.6)0 (0.0)
Sepsis associated with enteritis1 (1.6)0 (0.0)
Other AEs
Worsening of glycemic control2 (3.2)1 (1.6)
Acute epiglottitis1 (1.6)0 (0.0)
Dental caries1 (1.6)0 (0.0)
Liver dysfunction1 (1.6)0 (0.0)
Muscular pain1 (1.6)0 (0.0)
Fall0 (0.0)1 (1.6)
Lumbago0 (0.0)1 (1.6)
Elevation of serum CK0 (0.0)1 (1.6)

Adverse events.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Summary

Keywords

apolipoprotein B-48, atherosclerotic cardiovascular disease, residual risk, hypertriglyceridemia, pemafibrate, polyunsaturated fatty acids

Citation

Takeda Y, Sakuma I, Hiramitsu S, Okada M, Ueda S and Sakurai M (2023) Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study). Front. Cardiovasc. Med. 10:1172664. doi: 10.3389/fcvm.2023.1172664

Received

23 February 2023

Accepted

02 March 2023

Published

16 March 2023

Volume

10 - 2023

Edited and reviewed by

Ichiro Manabe, Chiba University, Japan

Updates

Copyright

*Correspondence: Yasutaka Takeda

Specialty Section: This article was submitted to Cardiovascular Metabolism, a section of the journal Frontiers in Cardiovascular Medicine

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics